Radiopharm Theranostics Entitlement Offer Shortfall Placement

Radiopharm Theranostics Limited (ASX: $RAD) has successfully secured commitments totaling approximately A$1.7 million for the Shortfall under the Entitlement Offer. The 24,025,716 New Shares will be issued at the same price per share as the Entitlement Offer, amounting to $0.07 per New Share, and will rank equally in all respects with existing shares on issue. The funds raised will be utilized to support the company's clinical programs.

Radiopharm CEO Riccardo Canevari's Statement

We would like to thank our existing and incoming investors for their support of our programs, our pipeline and our team.

Radiopharm Theranostics Entitlement Offer Outcome

Radiopharm Theranostics Limited (ASX: $RAD) has successfully secured commitments totaling approximately A$1.7 million for the Shortfall under the Entitlement Offer. The funds raised will be utilized to support the company's clinical programs. The company's clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including breast, kidney, and brain. Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The company has a pipeline of six distinct and highly differentiated platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world's leading universities and institutes.